NovaVax vaccine. Photo novabacks
The government is promoting the domestic introduction of a novel coronavirus infection (Corona 19) vaccine (NVX-CoV2373) from the US pharmaceutical company NovaVax.
Possibility of introduction after commercialization in the first quarter of this year
The quantity seems to be around 10 million bottles
According to the domestic biopharmaceutical industry on the 12th, the government is negotiating a final vaccine supply contract with NovaVax. It is predicted that the quantity will be around 10 million people. If the contract proceeds as planned, it will increase more than the 55 million people secured so far (10 million AstraZeneca and Pfizer each, 20 million modders, 6 million Janssen, and 10 million Kovacs).
NovaVax vaccine has the advantage that domestic supply is easy as it was already contracted last year by a domestic company SK Bioscience to produce it on consignment. It is also evaluated as having excellent efficacy because it is a vaccine made using the corona virus’s spike (projection) protein. Refrigerated storage (video 2-8 degrees) is also possible.
Prime Minister Jeong Sye-gyun. yunhap news
NovaVax vaccine is undergoing phase 3 clinical trials. Phase 3 clinical trials are being conducted in the UK (15,000 people) last September and the United States and Mexico (30,000 people) at the end of last year. It can be introduced into Korea after commercialization in the first quarter of this year.
Prime Minister Jeong Sye-gyun said at a meeting of the Central Disaster and Safety Countermeasures Headquarters this morning, “The government has made efforts to introduce a vaccine from another platform so that the people can be vaccinated with confidence.” Details will be reported in detail as soon as the contract is finalized.”
Reporter Esther and Kim Min-wook [email protected]